

These amendments are made without prejudice and are not to be construed as abandonment of the previously claimed subject matter or agreement with the Examiner's position. In accordance with the requirements of 37 C.F.R. § 1.121, a marked up version showing the changes to the claims, is attached herewith as Appendix A.

REMARKS

Sequence Listing.

This amendment is provided in Response to the Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant(s) request entry of this amendment in adherence with 37 C.F.R. §§1.821 to 1.825. This amendment is accompanied by a floppy disk containing the sequences (SEQ ID NOs:1-133) in computer readable form, and a paper copy of the sequence information that has been printed from the floppy disk.

Also enclosed is a "Statement of Support Filing and Submission in Accordance with 37 C.R.F. §§ 1.1821-1.925", by James A. Coburn of Harbor Consulting, the preparer of the sequence listing, indicating that the information contained in the computer readable form (floppy disk) is identical to that of the paper copy.

This amendment contains no new matter. The amendments to the specification and/or claims are to provide a formal sequence listing and/or to provide appropriate cross-references to SEQ ID Numbers in accordance with 37 C.F.R. §§1.821 to 1.825. The sequence information provided herein finds support in the specification as filed.

Change in Correspondence Address.

A Revocation and Substitute Power of Attorney incorporating a change in correspondence address accompanies this document. In accordance with the instructions provided therein, please direct all future correspondence regarding the subject application to CUSTOMER NUMBER 22798, that is:

Page 8



PATENT TRADEHARK OFFICE

LAW OFFICES OF JONATHAN ALAN QUINE

P.O. BOX 458

Alameda, CA 94501

Tel: (510) 337-7871 / Fax: (510) 337-7877

If a telephone conference would expedite prosecution of this application, the Examiner is invited to telephone the undersigned at (510) 337-7871.

LAW OFFICES OF JONATHAN ALAN QUINE

P.O. BOX 458

Alameda, CA 94501 Tel: 510 337-7871 Fax: 510 337-7877 Respectfully submitted,

Tom Hunter

Attorney for Applicant(s)

Reg. No: 38,498

Encl:

1) Copy of Notice to Comply With Requirement for Patent Applications Containing Nucleotide Sequence . . .

2) Sequence listing paper copy and computer readable form (CRF)

3) Petition for 1 month extension of time.

Application No.: 09/477,962 Page 9



VERSION WITH MARKINGS TO SHOW CHANGES MADE IN 09/477,962 WITH ENTRY OF THIS AMENDMENT

In the specification:

Page 3, lines 14-25:

In one embodiment, this invention provides an isolated nucleic acid comprising a nucleic acid selected from the group consisting of a nucleic acid encoding any one of Blm open reading frames (ORFs) 8 through 41, and/or a nucleic acid encoding a polypeptide encoded by any one of Blm open reading frames (ORFs) 8 through 41, and/or a nucleic acid amplified by polymerase chain reaction (PCR) using any one of the primer pairs identified in Table II and the nucleic acid of a bleomycin-producing organism as a template. The nucleic acid may comprise one or multiple (e.g. two, more preferably 3 or more) bleomycin open reading frames (i.e. BLM ORFs 8 through 41). One preferred nucleic acid comprises a nucleic acid encoding a C domain lacking one or more His residues of the conserved HHxxxDG (SEQ ID NO:4) active site for transpeptidation. In another preferred embodiment the nucleic acid comprises a nucleic acid encoding a protein encoded by a gene selected from the group consisting of blmI, blmII, and blmXI.

Page 15, lines 18-31:

Figure 8A shows a restriction map of the *blm* gene cluster from *Sv* ATCC15003 (B, *Bam*HI). 8B shows the relative position of the *blmI*, *blmII*, and *blmXI* genes to the two *blmAB* resistance genes (*blm^R*, Blm resistance). Individual open reading frames are represented by open arrows. Figure 8C (SEQ ID NO:127 & 128) shows the nucleotide sequence of the *blmI* gene. The potential ribosome-binding site (RBS) and the conserved motif for 4'-phosphopantetheinylation are underlined. The sequence has been deposited into GenBank under accession no. AF210249.

Figure 9 shows an amino acid sequence comparison of BlmI (SEQ ID NO:133) with PCP domains of known type I NRPSs (Grs-2 [P14688] (SEQ ID NO:129), 36% identity, 58% similarity; Srfa-3 [Q08787] (SEQ ID NO:130), 40% identity, 64% similarity; Vir-s [Y11547] (SEQ ID NO:131), 36% identity, 60% similarity; Saf-b [U24657] (SEQ ID NO:132), 40% identity, 54% similarity). Given in brackets are nucleotide sequence accession numbers. The shaded letters indicate similar amino acids.

Page 10

Consensus residues are amino acids that are similar in more than three sequences. The signature motif for 4'-phosphopantetheinylation is underlined.

Page 68, line 8 through page 69, line 16:

The similarities among PPTases from different organisms are reduced to two short motifs separated by 40-45 residues: (V/I)G(V/I)D (SEQ ID NO:87), and (F/W)(S/C/T)XKE(A/S)hhK (SEQ ID NO:91) (Lambalot et al. Chem. Biol. (1996) 3:923-936; Walsh et al. Curr. Opin. Chem. Biol. (1997) 1:309-315). Our previous attempts to amplify PPTase sequences from S. verticillus chromosomal DNA using degenerate primers according to the two conserved motifs were unsuccessful (unpublished results), so we decided to narrow our target. PPTases have been classified in two groups, according to their specificity for the carrier-protein substrate: PPTases involved in polyketide/fatty acid biosynthesis use acyl carrier proteins (ACPs) as substrate, while those for non-ribosomal peptide biosynthesis use peptidyl carrier proteins (PCPs) or aryl carrier proteins (ArCPs) (Walsh et al. Curr. Opin. Chem. Biol. (1997) 1:309-315). Several "NRPS-type" PPTase sequences were used to screen the databases to look for actinomycete homologues, and four proteins of unknown function were found: NshC from Streptomyces actuosus (Li et al. Gene (1990) 91:9-17), SC5A7. 23 from S. coelicolor (GenBank AL031107), an unnamed protein from Streptomyces sp. strain TH1 (Mori et al. J. Bacteriol. (1997) 179:5677-5683), and Rv2794c (later renamed PptT (Quadri et al. Chem. Biol. (1998) 5:631-645)) from Mycobacterium tuberculosis (GenBank AL008967). The alignment of the actinomycete sequences showed the two motifs conserved in all PPTases and an additional motif - the "THC" motif: PXWPXGX2GS(M/L)THCXGY (SEO ID NO:86), located about 15 amino acids upstream of the (V/I)G(V/I)D motif (SEQ ID NO:87). The "THC" motif is not universally conserved in all PPTases, but it can be detected also in some nonactinomycete PPTases like EntD (Coderre et al. J. Gen. Microbiol. (1989) 135:3043-3055). Using a recently developed method of PCR primer design (the CODEHOP strategy (COnsensus-DEgenerate Hybrid Oligonucleotide Primer) (Rose et al. Nucleic Acids Res. (1998) 26:1628-1635), two primers were designed around the typical C-terminal PPTase motif (primers KEA-1: 5'-T GCA GCA GAA CAG GAG GCK NYC CCA NKG-3' (SEQ ID NO:88) and KEA-2: 5'-TG GGT CAG CGG GTA CCA NRC YTT RWA-3' (SEO ID NO: 89, H=C+A, N=A+C+T+G, Y=C+T, K=G+T, R=A+G, W=T+A)), and one primer was designed from the "THC" motif (primer THC: 5'-C GGC ATG GTC GGC TCC HTN ACN CAY TG-3', SEQ ID NO:90, H=C+A, N=A+C+T+G, Y=C+T, K=G+T, R=A+G, W=T+A); this motif is not universally conserved in PPTases of all organisms). Using S. verticillus chromosomal DNA as template,

Page 11

no amplification product was detected using the THC and the KEA-1 primers. The set of primers THC/KEA-2 successfully amplified a single band of the expected size (about 250 bp), which was gelpurified and cloned. Eight individual clones were sequenced, and all of them resulted to be identical (except differences due to primer utilization) and highly similar to the putative actinomycete PPTases. The PCR fragment was used as a probe to screen a *S. verticillus* genomic library by colony hybridization. Of the 10,000 colonies screened, 25 positive clones were identified, and then confirmed by Southern analysis to contain the same 4. 6-kb *Bam*HI hybridizing band. The 4. 6-kb DNA fragment was subcloned, and the nucleotide sequence of a 1,761-bp *Bam*HI-*Sal*I region was determined (SEQ ID NO. 3).

Page 69, line 17 through page 70, line 20:

The sequence of the 1,761-bp BamHI-SalI fragment was analyzed for coding regions by using the CODONPREFERENCE and TESTCODE programs of the GCG package (Genetics Computer Group, Madison, Wisconsin). Two complete ORFs (pptA, orf3) and two incomplete ORFs (orf1, orf4) were identified within the sequenced region (Figure 13). The first ORF from left to right (designated orf1) starts out of the analyzed area and ends with a TGA codon at position 248 of the sequenced fragment. Comparison of the deduced product of orf1 with proteins in databases showed similarities with Rv2795c from Mycobacterium tuberculosis (GenBank AL008967) and SC5A7. 22 from S. coelicolor (GenBank AL031107), both of unknown function. The second ORF, pptA, contains the sequence amplified by PCR and used for the cloning of this locus. It comprises 741 nucleotides, starting with a GTG codon (position 245) which is coupled to the stop codon of orf1, and ending with a TAA codon. The starting codon of pptA is preceded by a potential ribosomal binding site (RBS), GGGAG. The overall (76.6%) and third codon position (93. 9%) G+C contents and the codon usage of pptA are similar to those found in other Streptomyces genes, with the exception of the stop codon (TAA), which is most uncommon in this group of organisms (Wright et al. Gene (1992) 113:55-65). The pptA gene encodes a protein of 246 amino acids with a predicted molecular mass of 25,619 Da and a pI of 4. 76, which contains the conserved PPTase motifs. Databases searches with PptA showed significant similarities to the putative actinomycete PPTases (39-52%/48-61% identity/similarity) and to confirmed bacterial PPTases such as EntD from E. coli (17%/24% identity/similarity) (Lambalot et al. Chem. Biol. (1996) 3:923-936). The third ORF, orf3, is separated from pptA by an apparently noncoding DNA region of 153 bp, and it is transcribed in opposite and convergent direction with respect to orf1-pptA. The gene orf3 comprises 240 nucleotides, starting with an ATG codon (position 1358) and ending with TGA. The starting codon of orf3 is preceded by the

Page 12

sequence GAAGG, a potential RBS. The deduced product of *orf3* encodes a protein of 79 amino acids with a predicted mass of 7,555 Da and a pI of 7. 17. The Orf3 protein shows similarities to the N-terminal region of SC5H1. 35c, a protein of unknown function from *S. coelicolor* (GenBank AL049863). Analysis of Orf3 with the SignalP program (Nielsen et al. *Protein Engineer*. (1997) 10:1-6) predicts an N-terminal signal peptide which would be cleaved between residues 27 and 28 (ALA-DS), suggesting that the mature protein (52 amino acids, 5,099 Da, pI 4. 31) would be secreted. Between *orf3* and *orf4* there is an apparently noncoding region of 251 nucleotides. The *orf4* gene is transcribed in opposite and divergent direction with respect to *orf3*. It starts with an ATG codon at position 1610, preceded by a potential RBS (GGAGG), and ends out of the sequenced fragment. The deduced protein product (50 amino acids) of the incomplete *orf4* contains a potential NAD/FAD binding motif, GXGX₂GX₃GX₆G (SEQ ID NO:92) (Scrutton et al. *Nature* (1990) 343:38-43), showing low similarities to diverse oxidoreductases.

Pages 21-23:

Table II. Blm gene cluster open reading frames (ORFs) and primers for ORF amplification.


Orf#	Position	Activity	Method	Primers	Seq
•				Forward	ID
				Reverse	No.
orf-8	76183-	Oxygen-independent	Gapped-blast	F: ATGAGCCACGCCATCGGA	5
SEQ ID NO:115	77457	coproporphyrinogen III	comparison	R: TCAGGCGCGTTCGGGGGC	6
		oxidase	•		
orf-9	74690-	ADP-heptose synthase	Gapped-blast	F: GTGAACACCGACCTGCCC	7
SEQ ID NO:114	76186	(blmC)	comparison ¹	R: TCATGGGGTGTCTCCCTC	8
orf-10	74421-	Peptidyl carrier protein	Expression and	F: ATGAGCGCCCGCGGGGC	9
SEQ ID NO:113	74693	(blmI)	biochemical	R: TCACCGGTCCCGCTCCCC	10
	1		characterization.2		
orf-11	72787-	Carbamyltransferase	Gapped-blast	F: ATGAGCGCCGACCCGTCC	11
SEQ ID NO:112	74424	(blmD)	comparison ¹	R: TCATGAGCGGGCCGCCGT	12
orf-12	71618-	ADP-heptose:LPS heptosyl	Gapped-blast	F: ATGACCACCCCATGACC	13
SEQ ID NO:111	72790	transferase (blmE)	comparison ¹	R: TCATGGGGTACTCCTGAT	14
orf-13	70983-	Homolog of mbtH in the	Gapped-blast	F: ATGACCACGACCCCGCGG	15
SEQ ID NO:110	71546	synthesis of mycobactin	comparison ¹	R: TCAGGTGCCGGACACGCG	16
orf-14	69598-	Peptide synthetase	Gapped-blast	F: GTGACCGCCCCGGCACA	17
SEQ ID NO:109	70986	(condensation, blmII)	comparison	R: TCATCGGTGGCTCCTCGT	18
			1		
orf-15	68582-	Regulatory gene (homolog	Gapped-blast	F: GTGAACCGGCACGGCCCC	19
SEQ ID NO:108	69601	of syrP)	comparison	R: TCACGCGCTCACCTCGTC	20
orf-16	65778-	Mutated peptide synthetase-	Gapped-blast	F: GTGACGAGCGCCCGGCCC	21
SEQ ID NO:107	68585	oxidase (NRPS-0, blmIII)	comparison ¹	R: TCACGGGGCCTCCGTGCG	22
orf-17	57901-	Peptide synthetase	Expression and	F: ATGCTGCACGGCGCCGCG	23
SEQ ID NO:106	65781	(NRPS-2-1,blmIV)	biochemical	R: TCACTCCGGTCCACCTCC	24
	[characterization. ²		
orf-18	55899-	Asparagine synthetase	Gapped-blast	F: GTGAGGCCCGTGTGCGGC	25
SEQ ID NO:105	57815		comparison	R: TCAGCCACCGTTGCCGCC	26
orf-19	54418-	Homolog of hydroxylase-	Gapped-blast	F: GTGAAGGACCTCGGCCGG	27

Application No.: 09/477,962 Page 13

	genase trimital comparison	R: TCACTCCCCGGTGCCGG 2	
orf-20 53427- Nucleot	genuse in the comparison		28
	ide-sugar epimerase Gapped-blast	F: GTGACATGGACCGTGGTG 2	29
SEQ ID NO:103 54404 (blmG)	comparison	R: TCAGGCATCGGCCCTCCC 3	30
	synthetase Gapped-blast	F: ATGCGCGGGCATGACGAC 3	31
	3CT, blmV) comparison ¹	R: TCACGGTGTCTCTCCCTC 3	32
orf-22 43263- Peptide	synthetase Expression an	d F: ATGAGCCGGCCGGC 3	33
	5-4-3, blmVI) biochemical		34
	characterization	on. ²	
orf-23 39610- Peptide	synthetase Expression an		35
SEQ ID NO:100 43266 (NRPS-	6, blmVII) biochemical		36
	characterization	on. ²	
orf-24 34088- Polyket	ide synthase Gapped-blast		37
SEQ ID NO:99 39613 (blmVII)	(I) comparison ¹	R: TCACAGCACCACCTCTTC 3	38
orf-25 30891- Peptide	synthetase Gapped-blast	F: ATGACCCCGGCCGCCGAC 3	39
<u>SEQ ID NO:98</u> 34091 (NRPS-	7, blmIX) comparison ¹	R: TCATCGTCCGCCGCCTTT 4	40
	synthetase Gapped-blast	F: ATGCCTCGGTGTGCCCGA 4	41
	9-8, blmX) comparison ¹	R: TCATTCGGCGGCACCTCC 4	12
	synthetase Gapped-blast	F: GTGGGTTTCCGTCGAGCG 4	13
SEQ ID NO:96 24193 (conden	sation, blmXI) comparison ¹	R: TTACACCCTCCGTTTCTC 4	14
	atidylserine Gapped-blast	F: ATGGCACAGGACCTGAAC 4	45
SEQ ID NO:95 22086 decarbo		R: TCAACGCCACCGGATCTT 4	16
	embrane transporter Gapped-blast	F: GTGAGCTCCCTCGCCGTC 4	17
SEQ ID NO:94 20909	comparison ¹	R: TCATCGTCGGGCACTCGG 4	18
orf-30 18823- Metal de	ependent regulatory Gapped-blast	F: GTGCCGGTTCCGCTGTAT 4	19
SEQ ID NO:93 19164 element		R: TCACCGGGCACTGACCTC 5	50
orf-31 18660- PHNA I	nomolog Gapped-blast	F: GTGACCGAGAACCTTCCG 5	51
SEQ ID NO:116 18307	comparison	R: TCAGACCTTCTTGACCAC 5	52
orf-32 17736- Peptide	synthetase Gapped-blast	F: ATGGCCTCAGACGCTTTG 5	53
SEQ ID NO:117 9211 (NRPS-	11-10) comparison ¹	R: TCATTGAGACTCCTCCTC 5	54
orf-33 9214- Putative	transporter Gapped-blast	F: ATGATGAAGTCAAGCCGC 5	55
SEQ ID NO:118 7859	comparison 1	R: TCAGTGGCTTACAAGGAG 5	56
orf-34 7797- Homolo	g of clavaminic Gapped-blast	F: ATGACTGACCTGCCGTTG 5	57
SEQ ID NO:119 6784 acid syn	thase comparison ¹	R: TCACACCAGCAGCGAGGT 5	58
orf-35 6773- Thioeste	erase Gapped-blast		59
SEQ ID NO:120 6021	comparison	R: TCATGCCCCTACCTCGGC 6	50
orf-36 6024- Putative	transporter Gapped-blast		51
SEQ ID NO:121 4741	comparison ¹		52
orf-37 4733- Unknow	1 ** .	1	53
SEQ ID NO:122 3915	comparison ¹		54
	synthetase Gapped-blast		55
SEQ ID NO:123 2182 (NRPS-			56
	ory gene Gapped-blast		57
	og of <i>SyrP</i> comparison ¹		58
orf-40 1015-1 Peptide	synthetase Gapped-blast		59
SEQ ID NO:125	comparison ¹		70
	phopantetheinyl Expression an		71 .
SEQ ID NO:126 separate transfer	ase (pptA) biochemical		72
sequence	characterization	on. ²	

Page 14

In the claims:



28. The polypeptide claim 25, wherein said polypeptide comprises a C domain lacking one or more His residues of the conserved HHxxxDG (SEQ ID NO:4) active site for transpeptidation.